J Price1, R Shaarbaf, L Wood. 1. Department of Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB.
Abstract
BACKGROUND: Sunitinib is approved for treatment of advanced renal cell carcinoma (RCC). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation. METHODS: In a retrospective review of RCC patients treated at a single centre, data on treatment duration, hematology parameters, concomitant medications, vitamin B₁₂and folate levels, and thyroid function were recorded. RESULTS: The 43 patients reviewed had received a median of 5 cycles of sunitinib. Overall, 21 patients (49%) developed macrocytosis after a median of 3 cycles. Of the 9 patients that received 2 or fewer cycles, none developed macrocytosis. Among patients with macrocytosis, 9 (43%) had anemia at the time macrocytosis was first documented. In patients who did not develop macrocytosis, 82% showed a trend of increasing mean corpuscular volume. CONCLUSIONS: Treatment with sunitinib in patients with RCC can cause macrocytosis. The frequency of macrocytosis increases with duration of treatment. The mechanism of sunitinib-associated macrocytosis remains to be elucidated.
BACKGROUND:Sunitinib is approved for treatment of advanced renal cell carcinoma (RCC). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation. METHODS: In a retrospective review of RCCpatients treated at a single centre, data on treatment duration, hematology parameters, concomitant medications, vitamin B₁₂and folate levels, and thyroid function were recorded. RESULTS: The 43 patients reviewed had received a median of 5 cycles of sunitinib. Overall, 21 patients (49%) developed macrocytosis after a median of 3 cycles. Of the 9 patients that received 2 or fewer cycles, none developed macrocytosis. Among patients with macrocytosis, 9 (43%) had anemia at the time macrocytosis was first documented. In patients who did not develop macrocytosis, 82% showed a trend of increasing mean corpuscular volume. CONCLUSIONS: Treatment with sunitinib in patients with RCC can cause macrocytosis. The frequency of macrocytosis increases with duration of treatment. The mechanism of sunitinib-associated macrocytosis remains to be elucidated.
Authors: Brian I Rini; Ila Tamaskar; Phillip Shaheen; Renee Salas; Jorge Garcia; Laura Wood; Sethu Reddy; Robert Dreicer; Ronald M Bukowski Journal: J Natl Cancer Inst Date: 2007-01-03 Impact factor: 13.506
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Jayesh Desai; Leila Yassa; Ellen Marqusee; Suzanne George; Mary C Frates; Ming Hui Chen; Jeffrey A Morgan; Samuel S Dychter; P Reed Larsen; George D Demetri; Erik K Alexander Journal: Ann Intern Med Date: 2006-11-07 Impact factor: 25.391
Authors: Brian I Rini; Toni K Choueiri; Paul Elson; Mohamad K Khasawneh; Claudiu Cotta; Jaya Unnithan; Laura Wood; Tarek Mekhail; Jorge Garcia; Robert Dreicer; Ronald M Bukowski Journal: Cancer Date: 2008-09-15 Impact factor: 6.860
Authors: Catharina Wenzel; Robert M Mader; Guenther G Steger; Ursula Pluschnig; Gabriela V Kornek; Werner Scheithauer; Gottfried J Locker Journal: Anticancer Drugs Date: 2003-02 Impact factor: 2.248
Authors: Maria T Bourlon; Dexiang Gao; Sara Trigero; Julia E Clemons; Kathryn Breaker; Elaine T Lam; Thomas W Flaig Journal: Cancer Med Date: 2016-10-19 Impact factor: 4.452